Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study-Reference-Cited by-同舟云学术

Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study

Published:2023-02 Issue:2 Volume:5 Page:e88-e98
ISSN:2665-9913
Container-title:The Lancet Rheumatology
language:en
Short-container-title:The Lancet Rheumatology

Author:

Md Yusof Md Yuzaiful,Arnold Jack,Saleem Benazir,Vandevelde Claire,Dass Shouvik,Savic Sinisa,Vital Edward M,Emery Paul

Funder

Leeds Biomedical Research Centre

Wellcome Trust

National Institute for Health and Care Research

Eli Lilly and Company

Department of Health and Social Care

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference34 articles.

1. Coronavirus disease 2019 outcomes among recipients of anti-CD20 monoclonal antibodies for immune-mediated diseases: a comparative cohort study;Patel;ACR Open Rheumatol,2022

2. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry;Strangfeld;Ann Rheum Dis,2021

3. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry;Sparks;Ann Rheum Dis,2021

4. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study;Avouac;Lancet Rheumatol,2021

5. B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics;Felten;Ann Rheum Dis,2022

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SARS‐CoV‐2 Evolution: Immune Dynamics, Omicron Specificity, and Predictive Modeling in Vaccinated Populations;Advanced Science;2024-08-29

2. SARS-CoV-2 Variants and Clinical Outcomes of Special Populations: A Scoping Review of the Literature;Viruses;2024-07-30

3. COVID‐19 Vaccination Before Initiating Rituximab Treatment Induces Strong Serological Response in Autoimmune Rheumatic Disease, Reducing Post‐Pandemic Concerns About the Impact of Rituximab;ACR Open Rheumatology;2024-06-23

4. Effectiveness and Safety of the COVID-19 Vaccine in Patients with Rheumatoid Arthritis in a Real-World Setting;Vaccines;2024-06-18

5. Update on Omicron variant and its threat to vulnerable populations;Public Health in Practice;2024-06